UK-Based Glass Pharms Launches Branded Range of Medical Cannabis Products in Partnership with Pharmaceutical Manufacturer
Wednesday 31 July, 2024 – Glass Pharms, a leading UK-based medical cannabis cultivation company, has announced the launch of their own-branded range of Cannabis-based products for medicinal use (CBPMs). The products will be available at select pharmacies across the UK and are a result of a partnership with a UK pharmaceutical manufacturing company.
Using cannabis flower grown at their purpose-built 2.4-hectare facility in Wiltshire, Glass Pharms’ medicines offer a variety of prescribing options for UK clinicians and patients. This is a significant development as these options were previously inconsistently available. The initial launch includes a High-CBD flower with less than 1% THC, which a recent study by the University of Colorado Boulder suggests may be more effective in treating anxiety compared to other flowers with higher THC content.
According to James Duckenfield, CEO of Glass Pharms, “As well as producing High-THC Cannabis flower, we have a commitment to bring CBD-containing medical cannabis flower to the UK market as we believe it gives prescribers options for cannabis-naive patients that would otherwise be missing.” He also noted that careful titration of THC content has been shown to improve the initial patient experience and lead to better outcomes for new users of medical cannabis.
Other flowers available immediately include an entry-level High-THC flower and a high terpene content High-THC flower. Glass Pharms plans to introduce more cultivars in the coming months as part of their branded range.
The CBPMs will be manufactured to the new British Pharmacopeia (BP) standard for Cannabis flower, which became legally binding in the UK on July 1st of this year. This marks the return of Cannabis flower as a medicine to the British Pharmacopeia after it was removed for prohibitionist reasons in 1932. The flower is non-irradiated and produced to exacting microbial standards in Glass Pharms’ purpose-built facility, designed to produce Cannabis flower to pharmaceutical standards.
In addition to meeting pharmaceutical standards, Glass Pharms’ ultra-modern facility operates off-grid, powered by food waste converted into energy in an adjacent anaerobic digestion plant. This gives their cannabis flower a best-in-class sustainability profile.
For more information, please contact Mark Heley, External Relations at Glass Pharms, via email at mh@glasspharms.com or by phone at 07904 856199.
The launch of Glass Pharms’ branded range of medical cannabis products is a significant step towards providing patients with consistent and high-quality options for their medical needs. This development is in line with the new British Pharmacopeia standard for Cannabis flower, which recognizes its potential as a medicine. The company’s commitment to sustainability and adherence to pharmaceutical standards sets them apart as a leader in the UK medical cannabis industry.
1. Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study. https://www.liebertpub.com/doi/10.1089/can.2023.0187. Accessed on March 06, 2024. Distributed by https://pressat.co.uk/.
